Zacks Research Has Pessimistic Outlook of Neogen Q3 Earnings

Neogen Corporation (NASDAQ:NEOG) – Analysts at Zacks Research cut their Q3 2026 earnings estimates for shares of Neogen in a note issued to investors on Wednesday, December 17th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.07 per share for the quarter, down from their previous forecast of $0.08. The consensus estimate for Neogen’s current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen’s Q3 2027 earnings at $0.06 EPS, Q4 2027 earnings at $0.07 EPS, FY2027 earnings at $0.30 EPS and Q1 2028 earnings at $0.09 EPS.

Other equities research analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neogen in a research report on Monday. CJS Securities raised shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 target price for the company in a report on Wednesday, December 10th. Piper Sandler set a $6.50 price target on Neogen and gave the company a “neutral” rating in a research note on Thursday, October 16th. Finally, Wall Street Zen upgraded Neogen from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $8.83.

Neogen Stock Performance

Neogen stock opened at $7.20 on Friday. The company has a current ratio of 3.58, a quick ratio of 2.26 and a debt-to-equity ratio of 0.37. Neogen has a 1 year low of $3.87 and a 1 year high of $13.40. The company has a market cap of $1.56 billion, a PE ratio of -1.50 and a beta of 1.99. The company’s 50-day moving average is $6.22 and its two-hundred day moving average is $5.66.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Neogen by 1.6% in the third quarter. Vanguard Group Inc. now owns 23,963,223 shares of the company’s stock worth $136,830,000 after acquiring an additional 385,885 shares in the last quarter. ING Groep NV acquired a new position in shares of Neogen in the 3rd quarter valued at approximately $80,288,000. Clarkston Capital Partners LLC increased its stake in Neogen by 123.2% during the 2nd quarter. Clarkston Capital Partners LLC now owns 14,005,725 shares of the company’s stock worth $66,947,000 after purchasing an additional 7,729,650 shares in the last quarter. Gates Capital Management Inc. acquired a new stake in Neogen during the 1st quarter worth approximately $79,391,000. Finally, Norges Bank acquired a new stake in Neogen during the 2nd quarter worth approximately $43,387,000. 96.73% of the stock is currently owned by institutional investors.

About Neogen

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.